Gyre Therapeutics (GYRE) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Gyre Therapeutics (GYRE) over the last 10 years, with Q3 2025 value amounting to $0.03.
- Gyre Therapeutics' EPS (Weighted Average and Diluted) rose 20000.0% to $0.03 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.03, marking a year-over-year increase of 10205.48%. This contributed to the annual value of $0.05 for FY2024, which is 10354.61% up from last year.
- According to the latest figures from Q3 2025, Gyre Therapeutics' EPS (Weighted Average and Diluted) is $0.03, which was up 20000.0% from $0.01 recorded in Q3 2024.
- Gyre Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $1.64 for Q2 2022, and its period low was -$1.51 during Q4 2023.
- For the 5-year period, Gyre Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.22, with its median value being $0.01 (2024).
- As far as peak fluctuations go, Gyre Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 35625.0% in 2022, and later tumbled by 9878.05% in 2023.
- Quarter analysis of 5 years shows Gyre Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.64 in 2021, then plummeted by 48.15% to -$0.95 in 2022, then crashed by 59.26% to -$1.51 in 2023, then soared by 100.66% to $0.01 in 2024, then skyrocketed by 200.0% to $0.03 in 2025.
- Its EPS (Weighted Average and Diluted) stands at $0.03 for Q3 2025, versus $0.01 for Q3 2024 and $0.01 for Q2 2024.